RelugolixHormone TherapySafety Rating 8/10
Primary research areaAdvanced prostate cancer
Research-literature reference data, NOT patient instructions. Not for human use. Consult a licensed clinician for any human application.
Research dose range120 mg loading then 40 mg daily
AdministrationOral tablet
Safety8/10 · FDA-approved (Orgovyx)
NCAA D1Banned
Price Comparison
Compare vendors
No vendor pricing available for this peptide yet.
Overview
About Relugolix
Mechanism of action
Oral GnRH receptor antagonist; rapid testosterone suppression reversible on discontinuation
Safety profile
Hot flashes, cardiovascular events, bone loss · Approved for prostate cancer; oral delivery; hot flashes; well-characterized
🔔 Get notified when the price drops anywhere
No account required. We scan 30+ vendors daily — one email the moment any vendor drops Relugolix below your target.
Related pages